hepatocellular carcinoma
Conditions
Interventions
Test group:Local consolidation therapy combined with first-line hepatic artery infusion chemotherapy and immunotherapy
Control group:First line hepatic artery infusion chemotherapy and immunotherapy
Sponsors
Yueyang Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age range: 18-75 years old, male or female not limited; 2.Diagnosed as HCC through pathology or clinical examination (meeting AASLD criteria); 3. BCLC stage B or C, Child Pugh grade A or B7 (bilirubin = 1.5 × 10 ?/L, platelets >= 75 × 10 ?/L, hemoglobin = 90 g/L; Liver function: ALT/AST = 60 mL/min (calculated according to the Cockcroft Gault formula); 7.The patient voluntarily signs the informed consent form, has good compliance, and is able to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Previously received LCT (radiotherapy, ablation, TACE, etc.); 2. Combination of severe underlying diseases such as heart, lung, kidney, etc. (such as NYHA heart function = III, severe chronic obstructive pulmonary disease); 3. Active autoimmune diseases or the need for long-term use of glucocorticoids (dose>10 mg/d prednisone equivalent dose); 4. Previous history of severe irAEs treated with immunotherapy (such as grade 3-4 pneumonia and colitis); 5. Pregnant or lactating women; 6. Merge with other malignant tumors (excluding skin basal cell carcinoma or cervical carcinoma in situ cured for more than 5 years); 7. Uncontrollable infections (such as HBV DNA>1 × 10 4 IU/mL, without antiviral treatment).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate(ORR);disease control rate(DCR);overall survival(OS);adverse events(AEs); | — |
Countries
China
Contacts
Public Contactzhan dahe
Yueyang Central Hospital
Outcome results
None listed